Search

everythinglearnresearchcommunity

for

Search:↓

The enzyme 5α-reductase is important for proper blood vessel development during the fertility-related transformation of the uterus lining.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Genetic variations affect dutasteride treatment response for male pattern hair loss.

Hairless protein can both repress and activate vitamin D receptor functions, affecting gene regulation.

Tunisian children with hereditary vitamin D-resistant rickets showed improvement with calcium treatment, and new genetic mutations were identified.

New mutations in the VDR gene cause vitamin D-resistant rickets without hair loss.

The study concluded that androstendione and DHEA are important for diagnosing high male hormone levels in women with excessive hair growth.

The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.

The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.

Scalp hair 17-OHP and androstenedione levels can help monitor treatment in CAH patients.

Men with baldness have higher levels of specific proteins, suggesting local hormone production may play a role in hair loss.

3α, 17β-androstanediol-glucuronide is not a useful marker for androgen excess but may help monitor certain treatments.

A 17-year-old female with adrenogenital syndrome produces very high levels of androgens, which prevent complete feminization despite high estrogen doses.

The enzyme 5α-reductase type 1 is important for blood vessel development and fertility in the uterus.

People who carry the 21-Hydroxylase Deficiency gene are not more likely to have excessive male hormone levels.

Non-classical 21 hydroxylase deficiency is an underdiagnosed cause of female hair loss and polycystic ovarian syndrome.

A single amino acid change in the vitamin D receptor can disrupt its function and lead to hair loss.

The update highlights that non-classic congenital adrenal hyperplasia is common in women with excess male hormones, requires specific hormone tests for diagnosis, and has various treatment options depending on age and symptoms.

Congenital Adrenal Hyperplasia is a genetic disorder with two forms, causing symptoms like early puberty and severe acne, but can be identified through screening and treated with glucocorticoids.

3α-AdiolG is a good marker for androgen activity in women with excessive hair growth and decreases with anti-androgen treatment.

Dihydrotestosterone (DHT) and its active metabolites play a key role in various diseases, and the development of 5α-reductase inhibitors can help treat these conditions.

Finasteride effectively inhibits the enzyme steroid 5 alpha-reductase II.

The document concludes that patient outcomes for Congenital Adrenal Hyperplasia are often not ideal because of poor management and a need for better diagnosis and treatment methods.

Testing basal 17-HP levels is a good way to screen for nonclassic adrenal hyperplasia in women with high androgen levels.

A 36-year-old person with a female appearance but male chromosomes was diagnosed with a rare enzyme deficiency affecting sexual development.

Measuring androstanediol glucuronide in blood is useful for assessing and tracking treatment in women with excessive hair growth.

Diagnosing simple-virilizing congenital adrenal hyperplasia can be difficult and requires thorough testing and expert advice.

Two different mutations in the vitamin D receptor gene cause different symptoms and responses to treatment in Lebanese patients with hereditary rickets.

A new mutation in the CDH3 gene causes hair loss and vision problems in a young girl.

A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.